| Gastroparesis M Camilleri, V Chedid, AC Ford, K Haruma, M Horowitz, KL Jones, ... Nature reviews Disease primers 4 (1), 41, 2018 | 319 | 2018 |
| Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis P Vijayvargiya, S Jameie-Oskooei, M Camilleri, V Chedid, PJ Erwin, ... Gut 68 (5), 804-813, 2019 | 183 | 2019 |
| Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis P Vijayvargiya, M Camilleri, V Chedid, A Mandawat, PJ Erwin, MH Murad Gastroenterology 156 (6), 1650-1660, 2019 | 139 | 2019 |
| Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth V Chedid, S Dhalla, JO Clarke, BC Roland, KB Dunbar, J Koh, E Justino, ... Global advances in health and medicine 3 (3), 16-24, 2014 | 133 | 2014 |
| GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity H Kadouh, V Chedid, H Halawi, DD Burton, MM Clark, D Khemani, ... The Journal of Clinical Endocrinology & Metabolism 105 (5), 1552-1563, 2020 | 100 | 2020 |
| Characterization of upper gastrointestinal symptoms, gastric motor functions, and associations in patients with diabetes at a referral center V Chedid, J Brandler, P Vijayvargiya, SY Park, LA Szarka, M Camilleri Official journal of the American College of Gastroenterology| ACG 114 (1 …, 2019 | 74 | 2019 |
| Analysis of fecal primary bile acids detects increased stool weight and colonic transit in patients with chronic functional diarrhea P Vijayvargiya, M Camilleri, V Chedid, P Carlson, I Busciglio, D Burton, ... Clinical Gastroenterology and Hepatology 17 (5), 922-929. e2, 2019 | 56 | 2019 |
| Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study V Chedid, P Vijayvargiya, P Carlson, K Van Malderen, A Acosta, ... Neurogastroenterology & Motility 30 (7), e13313, 2018 | 44 | 2018 |
| Actionable biomarkers: the key to resolving disorders of gastrointestinal function M Camilleri, V Chedid Gut 69 (10), 1730-1737, 2020 | 41 | 2020 |
| De novo colitis associated with rituximab in 21 patients at a tertiary center JD Eckmann, V Chedid, KP Quinn, N Bonthu, V Nehra, LE Raffals Clinical Gastroenterology and Hepatology 18 (1), 252-253, 2020 | 40 | 2020 |
| Gender is a determinative factor in the initial clinical presentation of eosinophilic esophagitis KL Lynch, S Dhalla, V Chedid, WJ Ravich, EM Stein, EA Montgomery, ... Diseases of the Esophagus 29 (2), 174-178, 2016 | 40 | 2016 |
| Audit of the diagnosis of rectal evacuation disorders in chronic constipation V Chedid, P Vijayvargiya, H Halawi, SY Park, M Camilleri Neurogastroenterology & Motility 31 (1), e13510, 2019 | 36 | 2019 |
| Elobixibat for the treatment of constipation V Chedid, P Vijayvargiya, M Camilleri Expert review of gastroenterology & hepatology 12 (10), 951-960, 2018 | 33 | 2018 |
| Bone health in patients with inflammatory bowel diseases VG Chedid, SV Kane Journal of Clinical Densitometry 23 (2), 182-189, 2020 | 32 | 2020 |
| Gastric accommodation measurements by single photon emission computed tomography and two‐dimensional scintigraphy in diabetic patients with upper gastrointestinal symptoms V Chedid, H Halawi, J Brandler, D Burton, M Camilleri Neurogastroenterology & Motility 31 (6), e13581, 2019 | 28 | 2019 |
| Aquaporin expression in colonic mucosal biopsies from irritable bowel syndrome with diarrhea M Camilleri, P Carlson, V Chedid, P Vijayvargiya, D Burton, I Busciglio Clinical and translational gastroenterology 10 (4), e00019, 2019 | 27 | 2019 |
| Randomised study: effects of the 5‐HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis V Chedid, J Brandler, K Arndt, P Vijayvargiya, XJ Wang, D Burton, ... Alimentary Pharmacology & Therapeutics 53 (9), 1010-1020, 2021 | 26 | 2021 |
| Relamorelin for the treatment of gastrointestinal motility disorders V Chedid, M Camilleri Expert Opinion on Investigational Drugs 26 (10), 1189-1197, 2017 | 25 | 2017 |
| Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea M Camilleri, P Carlson, J BouSaba, S McKinzie, P Vijayvargiya, Y Magnus, ... Gut 72 (1), 54-65, 2023 | 24 | 2023 |
| Impact of bile acid diarrhea in patients with diarrhea-predominant irritable bowel syndrome on symptoms and quality of life J BouSaba, W Sannaa, S McKinzie, P Vijayvargiya, V Chedid, XJ Wang, ... Clinical Gastroenterology and Hepatology 20 (9), 2083-2090. e1, 2022 | 22 | 2022 |
Michael CamilleriProfessor of Medicine, Pharmacology and Physiology, Mayo Clinic在 mayo.edu 的电子邮件经过验证
